The Commission on Human Medicines (CHM) has fully endorsed the conclusions and recommendations of the expert working group on alteplase in the treatment of stroke, confirming that the benefit of alteplase outweighs the risk when used up to 4.5 hours after symptoms appear.
The commission supported full transparency and the publication of all information considered by the group. Some information has been redacted to protect the identity of individuals and details of unpublished data.
The group considered the data above to reach their conclusions.
See the summary of product characteristics (SPC) and the patient information leaflet (PIL) for more details on alteplase.